Kasra Amirdelfan, MD
Pain Management · Santa Ana
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 32 years
- Texas A & M University System, Hsc, College of Medicine, 1994
On the public record
- 1 Medical Board action on record
Offices
1 location · Integrated Pain Management Medical Group Inc · 42 clinicians in this group
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Amirdelfan’s office at (714) 975-7950 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A66427 · Current
Licensed to practise in California · since 1998 · expires 2028-03-31 · Texas A & M University College of Medicine. Board flags: Public Reprimand.
Public record actions
| 2017-05-10 | Board disciplineDiscipline | Public letter of reprimand. · 8002015018883 |
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Family Medicine - Family Medicine
- American Board of Pain Medicine - Pain Medicine
Medicaid work
$46,291 in 2022
Medicaid paid $46,291 for 820 billed services this clinician did in 2022, up to 64 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 320 | $23,847 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 125 | $6,266 |
| Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour | 88 | $5,849 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 34 | $5,725 |
| Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes | 161 | $3,262 |
| Principal care management services, for a single high-risk disease, with the following required elements: one complex chronic condition expected to last at least 3 months, and that places the patient at significant risk of hospitalization, acute exacerbation/decompensation, functional decline, or death, the condition requires development, monitoring, or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen and/or the management of the condition is unusually complex due to comorbidities, ongoing communication and care coordination between relevant practitioners furnishing care; first 30 minutes of clinical staff time directed by physician or other qualified health care professional, per calendar month. | 39 | $1,317 |
| PROLNG E/M SVC BEFORE&/AFTER DIR PT CARE 1ST HR | 12 | $25 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 41 | $0 |
| 2022 | 820 | 8 | 64 | $46,291 |
| 2021 | 1,871 | 7 | 87 | $107,508 |
| 2020 | 1,217 | 5 | 91 | $39,844 |
| 2019 | 263 | 1 | 32 | $9,577 |
See the largest Medicaid services in earlier years
2021
| Return visit (30+ min) | 429 | $45,875 |
| Short return visit (20+ min) | 296 | $20,312 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 751 | $17,721 |
| Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour | 142 | $11,989 |
| Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes | 201 | $6,633 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 30 | $4,978 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 22 | $0 |
2020
| Short return visit (20+ min) | 509 | $22,498 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 592 | $13,656 |
| Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes | 59 | $2,344 |
| Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour | 16 | $1,333 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 41 | $12 |
2019
| Short return visit (20+ min) | 263 | $9,577 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 37% of their 229 Part D prescriptions in 2021. Long-acting opioids: 20% of their opioid prescriptions.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2022 | 38 | 23 | None | None | $3,811 |
| 2021 | 229 | 103 | 37% (84) | 6% | $11,360 |
| 2020 | 548 | 186 | 41% (224) | 3% | $17,523 |
| 2019 | 1,636 | 293 | 39% (644) | 10% | $95,980 |
| 2018 | 1,841 | 322 | 48% (884) | 10% | $139,128 |
| 2017 | 2,439 | 318 | 52% (1,258) | 10% | $168,748 |
| 2016 | 3,153 | 366 | 59% (1,872) | 13% | $337,319 |
| 2015 | 2,821 | 351 | 54% (1,528) | 9% | $217,199 |
| 2014 | 2,091 | 249 | 49% (1,033) | 11% | $171,126 |
| 2013 | 1,409 | 176 | 54% (763) | 16% | $146,102 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 6 drugs
| Gabapentin | 27 | $718 | $27 |
| Hydrocodone-Acetaminophen | 34 | $640 | $19 |
| Oxycodone-Acetaminophen | 15 | $450 | $30 |
| Pregabalin | 14 | $444 | $32 |
| Cyclobenzaprine | 13 | $368 | $28 |
| Cephalexin | 36 | $175 | $5 |
2020: 15 drugs
| Hydrocodone-Acetaminophen | 111 | $2,495 | $22 |
| Gabapentin | 62 | $1,259 | $20 |
| Oxycodone-Acetaminophen | 34 | $1,199 | $35 |
| Pregabalin | 20 | $934 | $47 |
| Diclofenac | 15 | $689 | $46 |
| Oxycodone | 19 | $486 | $26 |
| Morphine Sulfate Er | 16 | $481 | $30 |
| Tizanidine | 36 | $403 | $11 |
| Cyclobenzaprine | 27 | $194 | $7 |
| Cephalexin | 40 | $185 | $5 |
| Tramadol | 18 | $152 | $8 |
| Baclofen | 11 | $107 | $10 |
| Trazodone | 15 | $79 | $5 |
| Ibuprofen | 11 | $70 | $6 |
| Zolpidem | 11 | $52 | $5 |
2019: 26 drugs
| Lyrica | 23 | $20,795 | $904 |
| Oxycontin | 19 | $8,116 | $427 |
| Movantik | 19 | $8,079 | $425 |
| Narcan | 54 | $7,388 | $137 |
| Hydrocodone-Acetaminophen | 246 | $6,135 | $25 |
| Gabapentin | 225 | $5,036 | $22 |
| Oxycodone-Acetaminophen | 115 | $4,217 | $37 |
| Oxycodone | 93 | $2,775 | $30 |
| Voltaren | 13 | $2,737 | $211 |
| Diclofenac | 33 | $1,885 | $57 |
| Fentanyl | 24 | $1,457 | $61 |
| Tizanidine | 111 | $1,432 | $13 |
| Morphine Sulfate Er | 53 | $1,231 | $23 |
| Amitriptyline | 44 | $607 | $14 |
| Celecoxib | 23 | $507 | $22 |
| Ibuprofen | 67 | $503 | $8 |
| Baclofen | 29 | $454 | $16 |
| Duloxetine | 20 | $402 | $20 |
| Tramadol | 42 | $327 | $8 |
| Zolpidem | 46 | $321 | $7 |
| Cyclobenzaprine | 46 | $308 | $7 |
| Hydromorphone | 22 | $298 | $14 |
| Trazodone | 37 | $288 | $8 |
| Cephalexin | 31 | $153 | $5 |
| Methadone | 12 | $87 | $7 |
| Carisoprodol | 11 | $50 | $5 |
2018: 31 drugs
| Lyrica | 40 | $28,756 | $719 |
| Oxycontin | 49 | $17,437 | $356 |
| Oxycodone-Acetaminophen | 142 | $10,048 | $71 |
| Hydrocodone-Acetaminophen | 319 | $9,186 | $29 |
| Gabapentin | 241 | $5,329 | $22 |
| Movantik | 11 | $4,521 | $411 |
| Morphine Sulfate Er | 102 | $3,930 | $39 |
| Oxycodone | 99 | $3,447 | $35 |
| Fentanyl | 34 | $2,959 | $87 |
| Celecoxib | 23 | $2,836 | $123 |
| Voltaren | 14 | $2,522 | $180 |
| Diclofenac | 15 | $1,685 | $112 |
| Lidocaine | 13 | $1,447 | $111 |
| Chlorzoxazone | 26 | $1,409 | $54 |
| Tizanidine | 58 | $1,144 | $20 |
| Duloxetine | 28 | $830 | $30 |
| Baclofen | 37 | $776 | $21 |
| Hydromorphone | 36 | $577 | $16 |
| Ibuprofen | 42 | $369 | $9 |
| Trazodone | 62 | $345 | $6 |
| Zolpidem | 54 | $332 | $6 |
| Tramadol | 42 | $276 | $7 |
| Methadone | 21 | $272 | $13 |
| Amitriptyline | 31 | $270 | $9 |
| Omeprazole | 15 | $258 | $17 |
| Cyclobenzaprine | 30 | $258 | $9 |
| Ropinirole | 21 | $242 | $12 |
| Bupropion Hcl Sr | 12 | $195 | $16 |
| Morphine Sulfate | 11 | $181 | $16 |
| Cephalexin | 36 | $177 | $5 |
| Carisoprodol | 17 | $74 | $4 |
2017: 35 drugs
| Oxycontin | 87 | $28,269 | $325 |
| Lyrica | 42 | $21,674 | $516 |
| Oxycodone-Acetaminophen | 201 | $17,551 | $87 |
| Hydrocodone-Acetaminophen | 456 | $11,980 | $26 |
| Gabapentin | 284 | $8,022 | $28 |
| Fentanyl | 66 | $6,828 | $103 |
| Morphine Sulfate Er | 104 | $5,365 | $52 |
| Oxycodone | 132 | $4,335 | $33 |
| Lidocaine | 22 | $3,969 | $180 |
| Oxycodone Hcl Er | 13 | $3,583 | $276 |
| Voltaren | 11 | $2,626 | $239 |
| Celecoxib | 15 | $1,786 | $119 |
| Diclofenac | 20 | $1,529 | $76 |
| Zolpidem Tartrate Er | 14 | $1,448 | $103 |
| Baclofen | 47 | $1,210 | $26 |
| Duloxetine | 40 | $1,179 | $29 |
| Tizanidine | 80 | $1,164 | $15 |
| Hydromorphone | 51 | $927 | $18 |
| Cyclobenzaprine | 36 | $611 | $17 |
| Tramadol | 69 | $565 | $8 |
| Chlorzoxazone | 15 | $531 | $35 |
| Trazodone | 68 | $503 | $7 |
| Methadone | 29 | $458 | $16 |
| Bupropion Hcl Sr | 24 | $430 | $18 |
| Eszopiclone | 25 | $378 | $15 |
| Carisoprodol | 45 | $372 | $8 |
| Amitriptyline | 31 | $268 | $9 |
| Zolpidem | 67 | $256 | $4 |
| Ropinirole | 20 | $254 | $13 |
| Omeprazole | 23 | $223 | $10 |
| Ibuprofen | 38 | $205 | $5 |
| Ibu | 23 | $182 | $8 |
| Naproxen | 13 | $156 | $12 |
| Cephalexin | 32 | $152 | $5 |
| Methocarbamol | 11 | $102 | $9 |
2016: 33 drugs
| Evzio | 22 | $79,204 | $3,600 |
| Oxycontin | 149 | $61,376 | $412 |
| Lyrica | 75 | $33,402 | $445 |
| Hydrocodone-Acetaminophen | 669 | $24,634 | $37 |
| Oxycodone-Acetaminophen | 273 | $20,947 | $77 |
| Fentanyl | 118 | $11,816 | $100 |
| Morphine Sulfate Er | 196 | $9,212 | $47 |
| Gabapentin | 264 | $8,090 | $31 |
| Oxycodone Hcl Er | 17 | $6,482 | $381 |
| Oxycodone | 220 | $5,889 | $27 |
| Lidocaine | 17 | $3,806 | $224 |
| Duloxetine | 56 | $2,574 | $46 |
| Celecoxib | 30 | $2,533 | $84 |
| Voltaren | 14 | $2,245 | $160 |
| Methadone | 67 | $1,649 | $25 |
| Tizanidine | 79 | $1,634 | $21 |
| Zolpidem Tartrate Er | 17 | $1,558 | $92 |
| Baclofen | 42 | $1,170 | $28 |
| Hydromorphone | 63 | $960 | $15 |
| Ibuprofen | 112 | $906 | $8 |
| Eszopiclone | 27 | $690 | $26 |
| Amitriptyline | 26 | $643 | $25 |
| Cyclobenzaprine | 63 | $554 | $9 |
| Trazodone | 79 | $528 | $7 |
| Hydroxyzine | 11 | $346 | $31 |
| Ropinirole | 28 | $334 | $12 |
| Tramadol | 63 | $307 | $5 |
| Bupropion Xl | 12 | $285 | $24 |
| Zolpidem | 38 | $275 | $7 |
| Carisoprodol | 39 | $255 | $7 |
| Cephalexin | 31 | $221 | $7 |
| Bupropion Hcl Sr | 14 | $220 | $16 |
| Nortriptyline | 14 | $124 | $9 |
2015: 32 drugs
| Oxycontin | 88 | $58,591 | $666 |
| Lyrica | 69 | $27,146 | $393 |
| Hydrocodone-Acetaminophen | 592 | $22,122 | $37 |
| Oxycodone-Acetaminophen | 190 | $13,039 | $69 |
| Morphine Sulfate Er | 173 | $10,550 | $61 |
| Gabapentin | 277 | $9,720 | $35 |
| Fentanyl | 85 | $7,872 | $93 |
| Lidocaine | 23 | $6,072 | $264 |
| Duloxetine | 46 | $4,743 | $103 |
| Oxycodone | 150 | $4,365 | $29 |
| Tizanidine | 70 | $3,255 | $46 |
| Methadone | 67 | $1,898 | $28 |
| Zolpidem Tartrate Er | 14 | $1,212 | $87 |
| Zolpidem | 102 | $1,151 | $11 |
| Ibuprofen | 109 | $942 | $9 |
| Hydromorphone | 58 | $894 | $15 |
| Carisoprodol | 63 | $848 | $13 |
| Baclofen | 28 | $846 | $30 |
| Naproxen | 17 | $812 | $48 |
| Cyclobenzaprine | 72 | $795 | $11 |
| Amitriptyline | 37 | $759 | $21 |
| Butalbital-Acetaminophen-Caffe | 17 | $753 | $44 |
| Endocet | 14 | $745 | $53 |
| Tramadol | 81 | $455 | $6 |
| Bupropion Xl | 13 | $392 | $30 |
| Ropinirole | 23 | $306 | $13 |
| Trazodone | 54 | $295 | $5 |
| Promethazine | 12 | $265 | $22 |
| Escitalopram | 15 | $194 | $13 |
| Cephalexin | 25 | $126 | $5 |
| Omeprazole | 14 | $110 | $8 |
| Diazepam | 12 | $58 | $5 |
2014: 33 drugs
| Oxycontin | 80 | $45,600 | $570 |
| Fentanyl | 110 | $17,883 | $163 |
| Lyrica | 37 | $11,403 | $308 |
| Hydrocodone-Acetaminophen | 381 | $10,633 | $28 |
| Oxycodone-Acetaminophen | 111 | $9,589 | $86 |
| Duloxetine | 44 | $8,833 | $201 |
| Lidocaine | 30 | $8,303 | $277 |
| Gabapentin | 218 | $7,155 | $33 |
| Morphine Sulfate Er | 71 | $5,731 | $81 |
| Oxycodone | 101 | $3,950 | $39 |
| Lidoderm | 14 | $3,752 | $268 |
| Endocet | 29 | $2,642 | $91 |
| Tizanidine | 49 | $1,777 | $36 |
| Promethazine | 16 | $1,558 | $97 |
| Carisoprodol | 78 | $1,466 | $19 |
| Zolpidem Tartrate Er | 16 | $1,336 | $83 |
| Cyclobenzaprine | 48 | $686 | $14 |
| Methadone | 43 | $686 | $16 |
| Ropinirole | 20 | $641 | $32 |
| Hydromorphone | 38 | $630 | $17 |
| Venlafaxine Hcl Er | 21 | $558 | $27 |
| Ibuprofen | 68 | $493 | $7 |
| Zolpidem | 78 | $465 | $6 |
| Tramadol | 41 | $334 | $8 |
| Methocarbamol | 18 | $281 | $16 |
| Butalbital-Acetaminophen-Caffe | 11 | $246 | $22 |
| Trazodone | 30 | $208 | $7 |
| Cephalexin | 32 | $187 | $6 |
| Escitalopram | 13 | $160 | $12 |
| Omeprazole | 14 | $136 | $10 |
| Mirtazapine | 13 | $123 | $9 |
| Clonazepam | 18 | $114 | $6 |
| Diazepam | 17 | $112 | $7 |
2013: 27 drugs
| Oxycontin | 78 | $51,941 | $666 |
| Fentanyl | 118 | $30,163 | $256 |
| Gabapentin | 144 | $6,737 | $47 |
| Hydrocodone-Acetaminophen | 262 | $6,679 | $25 |
| Lidoderm | 24 | $6,089 | $254 |
| Lyrica | 18 | $5,774 | $321 |
| Cymbalta | 19 | $4,664 | $245 |
| Pennsaid | 11 | $2,851 | $259 |
| Oxycodone | 85 | $2,692 | $32 |
| Oxycodone Hcl-Acetaminophen | 42 | $2,435 | $58 |
| Morphine Sulfate Er | 47 | $2,007 | $43 |
| Zolpidem Tartrate Er | 13 | $1,550 | $119 |
| Tizanidine | 36 | $654 | $18 |
| Carisoprodol | 35 | $485 | $14 |
| Cyclobenzaprine | 39 | $398 | $10 |
| Methadone | 24 | $395 | $16 |
| Hydromorphone | 25 | $292 | $12 |
| Tramadol | 37 | $284 | $8 |
| Mirtazapine | 12 | $242 | $20 |
| Zolpidem | 42 | $226 | $5 |
| Omeprazole | 12 | $194 | $16 |
| Promethazine | 11 | $181 | $16 |
| Clonazepam | 17 | $134 | $8 |
| Cephalexin | 16 | $130 | $8 |
| Baclofen | 18 | $113 | $6 |
| Diazepam | 19 | $105 | $6 |
| Temazepam | 11 | $61 | $6 |
Money from drug and device companies
$13,554 in 2025
| 2025 | 4 | 24 | $11,725 | $13,554 |
| 2024 | 8 | 50 | $15,500 | $19,247 |
| 2023 | 6 | 53 | $50,564 | $59,628 |
| 2022 | 10 | 135 | $86,067 | $111,348 |
| 2021 | 9 | 169 | $135,473 | $158,752 |
| 2020 | 9 | 141 | $147,081 | $158,313 |
| 2019 | 10 | 242 | $230,465 | $262,435 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotronik Nro | Prospera | $7,828 | 17 payments
|
| Globus Medical | Senza | $4,285 | 4 payments
|
| Saluda Medical Americas | Evoke | $1,343 | 2 payments
|
| Abbott Laboratories | Proclaim | $99 | 1 payment
|
See all 24 published payments
| Biotronik Nro | Meals · 2025-11-20 | Prospera | $10 |
| Biotronik Nro | Meals · 2025-10-10 | Prospera | $29 |
| Biotronik Nro | Meals · 2025-10-08 | Prospera | $230 |
| Biotronik Nro | Travel · 2025-09-15 | Prospera | $142 |
| Biotronik Nro | Meals · 2025-09-11 | Prospera | $86 |
| Globus Medical | Paid to speak or teach · 2025-08-27 | Senza | $1,300 |
| Biotronik Nro | Meals · 2025-08-12 | Prospera | $152 |
| Biotronik Nro | Meals · 2025-08-12 | Prospera | $36 |
| Biotronik Nro | Meals · 2025-08-12 | Prospera | $47 |
| Biotronik Nro | Meals · 2025-08-12 | Prospera | $38 |
| Saluda Medical Americas | Consulting · 2025-08-08 | Evoke | $1,200 |
| Biotronik Nro | Paid to speak or teach · 2025-08-05 | Prospera | $4,200 |
| Globus Medical | Paid to speak or teach · 2025-07-29 | Senza | $1,625 |
| Globus Medical | Consulting · 2025-07-24 | Senza | $1,300 |
| Biotronik Nro | Meals · 2025-07-19 | None | $75 |
| Biotronik Nro | Meals · 2025-07-19 | Prospera | $68 |
| Saluda Medical Americas | Meals · 2025-07-17 | Evoke | $143 |
| Biotronik Nro | Meals · 2025-07-17 | Prospera | $85 |
| Biotronik Nro | Travel · 2025-07-15 | Prospera | $375 |
| Biotronik Nro | Meals · 2025-07-09 | Prospera | $112 |
| Biotronik Nro | Paid to speak or teach · 2025-06-20 | Prospera | $2,100 |
| Abbott Laboratories | Meals · 2025-06-06 | Proclaim | $99 |
| Globus Medical | Meals · 2025-02-13 | Senza | $60 |
| Biotronik Nro | Meals · 2025-01-18 | None | $44 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $19,247
| Biotronik Nro | Prospera | $12,189 | 18 payments
|
| Saluda Medical Americas | Evoke | $3,506 | 7 payments
|
| Painteq | Painteq | $1,576 | 15 payments
|
| Nevro | Senza | $1,401 | 4 payments
|
| Abbott Laboratories | Eterna | $252 | 2 payments
|
| Biotronik | Prospera | $200 | 1 payment
|
| Medtronic | Synchromedii | $83 | 2 payments
|
| Curonix | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A | $41 | 1 payment
|
2023: $59,628
| Nevro | Omnia | $43,416 | 28 payments
|
| Painteq | Painteq | $5,345 | 12 payments
|
| Biotronik Nro | Biotronik | $5,149 | 2 payments
|
| Saluda Medical Americas | Evoke Scs | $4,426 | 9 payments
|
| Biotronik | Biotronik | $1,200 | 1 payment
|
| Averitas Pharma | Qutenza | $93 | 1 payment
|
2022: $111,348
| Nevro | Omnia | $52,802 | 65 payments
|
| Painteq | Painteq | $22,704 | 50 payments
|
| Biotronik | None | $18,293 | 2 payments
|
| Medtronic | Intellis Adaptivestim | $14,488 | 8 payments
|
| Saluda Medical Americas | Evoke Scs | $1,957 | 4 payments
|
| Nalu Medical | Nalu Neurostimulation System | $799 | 1 payment
|
| Abbott Laboratories | Proclaim | $148 | 2 payments
|
| Stimwave Technologies | Stimq Receiver Stimulator Kit Channel A US W/Receiver | $117 | 1 payment
|
| Relievant Medsystems | Intracept | $22 | 1 payment
|
| Fidia Pharma USA | Hymovis | $19 | 1 payment
|
2021: $158,752
| Nevro | Omnia | $110,281 | 123 payments
|
| Biotronik | None | $27,000 | 2 payments
|
| Medtronic | Intellis | $12,898 | 18 payments
|
| Nalu Medical | Nalu Neurostimulation System | $4,218 | 3 payments
|
| Boston Scientific | Superion | $3,270 | 3 payments
|
| Painteq | Painteq | $913 | 11 payments
|
| Relievant Medsystems | Intracept | $99 | 5 payments
|
| AbbVie | Ubrelvy | $38 | 2 payments
|
| Abbott Laboratories | Proclaim Ipg | $35 | 2 payments
|
2020: $158,313
| Nevro | Senza Spinal Cord Stimulation System | $87,856 | 83 payments
|
| Biotronik | None | $38,465 | 11 payments
|
| Medtronic USA | Intellis | $20,738 | 28 payments
|
| Nalu Medical | Nalu Neurostimulation System | $9,996 | 6 payments
|
| Boston Scientific | Superion | $1,129 | 7 payments
|
| Abbott Laboratories | Proclaim Family of Scs Ipgs | $86 | 3 payments
|
| Relievant Medsystems | Intracept | $18 | 1 payment
|
| US WorldMeds | Lucemyra/Lofexidine | $14 | 1 payment
|
| Collegium Pharmaceutical | Xtampza | $11 | 1 payment
|
2019: $262,435
| Nevro | Senza Spinal Cord Stimulation System | $230,523 | 189 payments
|
| Biotronik | None | $29,196 | 21 payments
|
| Medtronic USA | Autofill | $1,732 | 3 payments
|
| SPR Therapeutics | Sprint Pns System | $503 | 1 payment
|
| Vertiflex | Superion Iss | $261 | 4 payments
|
| Pfizer | Lyrica | $115 | 19 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Lucemyra | $45 | 2 payments
|
| Collegium Pharmaceutical | Xtampza | $22 | 1 payment
|
| Abbott Laboratories | Proclaim Family of Scs Ipgs | $20 | 1 payment
|
| Boston Scientific | Spectra Wavewriter | $19 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Nevro Corp. · Chronic Peripheral Polyneuropathy Randomized Trial · 2019 | Their institution | $191,767 |
| Nevro Corp. · Chronic Peripheral Polyneuropathy Randomized Trial · 2020 | Their institution | $142,125 |
| Nevro Corp. · Chronic Peripheral Polyneuropathy Randomized Trial · 2021 | Their institution | $109,775 |
| Nevro Corp. · Chronic Peripheral Polyneuropathy Randomized Trial · 2022 | Their institution | $46,146 |
| Mesoblast, Inc. · Msb-Dr004 · 2025 | Their institution | $45,330 |
| SPR Therapeutics, Inc · A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (Pns) for the Treatment of Back Pain · 2024 | Their institution | $37,128 |
| Globus Medical, Inc. · A Multi-Center Randomized Controlled Trial To Evaluate Pain and Neurological Function With 10 Khz Scs in Treatment of Painful Diabetic Neuropathy · 2025 | Their institution | $29,219 |
| Nalu Medical, Inc. · Spinal Cord Stimulation in Treatment of Chronic, Intractable Pain Using the Nalu Neuromodulation System · 2023 | Their institution | $27,353 |
| Nevro Corp. · Pdn-Sensory · 2024 | Their institution | $26,369 |
| Medtronic, Inc. · Dtm-Le Scs · 2021 | Their institution | $24,919 |
| SPR Therapeutics, Inc · A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (Pns) for the Treatment of Back Pain · 2023 | Their institution | $23,625 |
| Saluda Medical Americas, Inc. · Evoke Study · 2020 | Their institution | $22,828 |
| Nevro Corp. · Ca2018-1usrecharge · 2023 | Their institution | $16,525 |
| BIOTRONIK INC. · Benefit-02 · 2020 | Their institution | $15,450 |
| BIOTRONIK INC. · Benefit-02 · 2019 | Their institution | $14,713 |
| Saluda Medical Americas, Inc. · Evoke Study · 2019 | Their institution | $13,842 |
| Medtronic, Inc. · Dtm-Le Scs · 2022 | Their institution | $12,159 |
| Nevro Corp. · Ca2022-1 US Recharge II · 2023 | Their institution | $11,666 |
| Boston Scientific Corporation · Scope · 2023 | Their institution | $11,435 |
| Nevro Corp. · Ide Study · 2020 | Their institution | $10,270 |
| BOSTON SCIENTIFIC CORPORATION · Press 2 · 2022 | Their institution | $9,671 |
| Nevro Corp. · Ide Study · 2019 | Their institution | $7,893 |
| Nevro Corp. · Recharge · 2024 | Their institution | $7,800 |
| Nalu Medical, Inc. · Spinal Cord Stimulation in the Treatment of Chronic Intractable Pain Using the Nalu Neurostimulation System · 2020 | Their institution | $7,418 |
| Nevro Corp. · Ca2022-1usrechargeii · 2023 | Their institution | $7,340 |
| Saluda Medical Americas, Inc. · Evoke Study · 2021 | Their institution | $7,200 |
| Nevro Corp. · Recharge II · 2024 | Their institution | $6,356 |
| SPR Therapeutics, Inc · A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (Pns) for the Treatment of Back Pain · 2025 | Their institution | $6,200 |
| Nevro Corp. · Ca20181usrecharge · 2023 | Their institution | $6,180 |
| Nalu Medical, Inc. · Spinal Cord Stimulation in Treatment of Chronic, Intractable Pain Using the Nalu Neuromodulation System · 2021 | Their institution | $6,149 |
| SPR Therapeutics, Inc · A Study of Percutaneous Peripheral Nerve Stimulation (Pns) for the Treatment of Back Pain · 2020 | Their institution | $6,143 |
| Nevro Corp. · Upper Limb and Neck Trial · 2019 | Their institution | $5,900 |
| Nevro Corp. · Ca2022-2 US · 2023 | Their institution | $5,625 |
| Nevro Corp. · Ca2018-1 US Recharge · 2023 | Their institution | $5,260 |
| Saluda Medical Americas, Inc. · Evoke Study · 2020 | This clinician | $5,000 |
| Nevro Corp. · Ca2022-2ussenzapdn · 2023 | Their institution | $4,500 |
| SPR Therapeutics, Inc · A Study of Percutaneous Peripheral Nerve Stimulation (Pns) for the Treatment of Back Pain · 2019 | Their institution | $4,000 |
| Nevro Corp. · Ide Study · 2021 | Their institution | $3,300 |
| Nevro Corp. · Q32023recharge13 · 2023 | Their institution | $3,150 |
| BOSTON SCIENTIFIC CORPORATION · Scope · 2022 | Their institution | $2,864 |
| Vertiflex, Inc. · The Press Registry · 2019 | Their institution | $2,600 |
| Boston Scientific Corporation · Press 2 · 2021 | Their institution | $2,437 |
| Boston Scientific Corporation · Scope · 2024 | Their institution | $2,246 |
| BOSTON SCIENTIFIC CORPORATION · The Press Registry · 2020 | Their institution | $2,100 |
| Globus Medical, Inc. · A Multi-Center, Prospective Clinical Study Investigating Effectiveness of A Novel Administration of 10 Khz Scs Therapy · 2025 | Their institution | $1,691 |
| BOSTON SCIENTIFIC CORPORATION · Press 2 · 2020 | Their institution | $843 |
| Nalu Medical, Inc. · Treatment of Chronic, Intractable Pain Using the Nalu Neurostimulation System: A Prospective Registry · 2022 | Their institution | $700 |
| Saluda Medical Americas, Inc. · Evoke Study · 2022 | Their institution | $375 |
| Boston Scientific Corporation · Press 2 · 2023 | Their institution | $365 |
| Saluda Medical Americas, Inc. · Evoke Study · 2023 | Their institution | $225 |
| Saluda Medical Americas, Inc. · Ecap Study · 2021 | This clinician | $16 |
Professional record
- NPI
- 1033113642
- Licence
- CA A66427California A66427: Current · expires 2028-03-31
- Trained
- Texas A & M University System, Hsc, College of Medicine, 1994 · 32 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 208VP0000X (208VP0000X)
- Mailing address
- 450 N Wiget Ln, Walnut Creek, CA, 94598
- NPI first listed
- 2005-06-10
- NPI last updated
- 2009-10-22
This is when the NPI record was last certified, not a medical board exam.